HARVARD BIOSCIENCE INC (HBIO) Stock Fundamental Analysis
NASDAQ:HBIO - US4169061052 - Common Stock
0.489 USD
+0.01 (+2.71%)
0.4957 USD
+0.01 (+1.37%)
Taking everything into account, HBIO scores 3 out of 10 in our fundamental rating. HBIO was compared to 54 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of HBIO have multiple concerns. HBIO is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
HBIO had positive earnings in the past year.
HBIO had a positive operating cash flow in the past year.
In the past 5 years HBIO always reported negative net income.
In the past 5 years HBIO always reported a positive cash flow from operatings.
1.2 Ratios
HBIO has a worse Return On Assets (-71.67%) than 88.89% of its industry peers.
Looking at the Return On Equity, with a value of -364.88%, HBIO is doing worse than 88.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.67% | ||
| ROE | -364.88% | ||
| ROIC | N/A |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HBIO has a Gross Margin of 56.89%. This is in the better half of the industry: HBIO outperforms 74.07% of its industry peers.
In the last couple of years the Gross Margin of HBIO has remained more or less at the same level.
HBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.89% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
2. Health
2.1 Basic Checks
HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HBIO has more shares outstanding
The number of shares outstanding for HBIO has been increased compared to 5 years ago.
HBIO has a worse debt/assets ratio than last year.
2.2 Solvency
HBIO has an Altman-Z score of -2.68. This is a bad value and indicates that HBIO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.68, HBIO is not doing good in the industry: 85.19% of the companies in the same industry are doing better.
HBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 8.44 | ||
| Altman-Z | -2.68 |
ROIC/WACCN/A
WACC10.27%
2.3 Liquidity
HBIO has a Current Ratio of 0.81. This is a bad value and indicates that HBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
HBIO's Current ratio of 0.81 is on the low side compared to the rest of the industry. HBIO is outperformed by 92.59% of its industry peers.
A Quick Ratio of 0.41 indicates that HBIO may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.41, HBIO is doing worse than 98.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 |
3. Growth
3.1 Past
HBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -71.43%.
Measured over the past years, HBIO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -19.73% on average per year.
The Revenue for HBIO has decreased by -12.24% in the past year. This is quite bad
Measured over the past years, HBIO shows a decrease in Revenue. The Revenue has been decreasing by -4.12% on average per year.
EPS 1Y (TTM)-71.43%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%23.48%
Revenue 1Y (TTM)-12.24%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-11.46%
3.2 Future
Based on estimates for the next years, HBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 27.08% on average per year.
The Revenue is expected to decrease by -1.15% on average over the next years.
EPS Next Y-57.5%
EPS Next 2Y27.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.8%
Revenue Next 2Y-1.15%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 24.45, HBIO is valued on the expensive side.
HBIO's Price/Earnings ratio is a bit cheaper when compared to the industry. HBIO is cheaper than 75.93% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.24. HBIO is around the same levels.
HBIO is valuated cheaply with a Price/Forward Earnings ratio of 5.05.
Based on the Price/Forward Earnings ratio, HBIO is valued cheaper than 100.00% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of HBIO to the average of the S&P500 Index (35.82), we can say HBIO is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.45 | ||
| Fwd PE | 5.05 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HBIO is valued a bit cheaper than the industry average as 79.63% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HBIO indicates a rather cheap valuation: HBIO is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.27 | ||
| EV/EBITDA | 16.59 |
4.3 Compensation for Growth
HBIO's earnings are expected to grow with 27.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.08%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for HBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.489
+0.01 (+2.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners72.67%
Inst Owner Change-26.64%
Ins Owners1.48%
Ins Owner Change10.72%
Market Cap21.78M
Analysts80
Price Target3.06 (525.77%)
Short Float %3.33%
Short Ratio0.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.73%
Min EPS beat(2)1.96%
Max EPS beat(2)75.49%
EPS beat(4)3
Avg EPS beat(4)-19.61%
Min EPS beat(4)-173.52%
Max EPS beat(4)75.49%
EPS beat(8)3
Avg EPS beat(8)-36.43%
EPS beat(12)5
Avg EPS beat(12)-34.08%
EPS beat(16)5
Avg EPS beat(16)-29.83%
Revenue beat(2)1
Avg Revenue beat(2)4.73%
Min Revenue beat(2)-1.72%
Max Revenue beat(2)11.18%
Revenue beat(4)1
Avg Revenue beat(4)-1.43%
Min Revenue beat(4)-14.86%
Max Revenue beat(4)11.18%
Revenue beat(8)1
Avg Revenue beat(8)-5.4%
Revenue beat(12)2
Avg Revenue beat(12)-5.25%
Revenue beat(16)3
Avg Revenue beat(16)-4.28%
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)-75%
EPS NY rev (1m)-50%
EPS NY rev (3m)-44.44%
Revenue NQ rev (1m)-6.9%
Revenue NQ rev (3m)-17.01%
Revenue NY rev (1m)-1.89%
Revenue NY rev (3m)-1.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.45 | ||
| Fwd PE | 5.05 | ||
| P/S | 0.25 | ||
| P/FCF | 5.27 | ||
| P/OCF | 3.29 | ||
| P/B | 1.38 | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.59 |
EPS(TTM)0.02
EY4.09%
EPS(NY)0.1
Fwd EY19.82%
FCF(TTM)0.09
FCFY18.97%
OCF(TTM)0.15
OCFY30.42%
SpS1.99
BVpS0.35
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.67% | ||
| ROE | -364.88% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.89% | ||
| FCFM | 4.65% |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
F-Score4
Asset Turnover1.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 8.44 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 36.42% | ||
| Cap/Sales | 2.81% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 223.33% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | -2.68 |
F-Score4
WACC10.27%
ROIC/WACCN/A
Cap/Depr(3y)33.21%
Cap/Depr(5y)26.48%
Cap/Sales(3y)2.31%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.43%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%23.48%
EPS Next Y-57.5%
EPS Next 2Y27.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.24%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-11.46%
Revenue Next Year-8.8%
Revenue Next 2Y-1.15%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4733.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.77%
OCF growth 3Y4.55%
OCF growth 5Y-29.12%